The Ozempic maker raised its full-year outlook for the third time this year on Wednesday as its Wegovy pill beat third-quarter sales forecasts, boosting the Danish firm’s bid to win back ground from US rival Eli Lilly.
Need help?
Contact usThe Ozempic maker raised its full-year outlook for the third time this year on Wednesday as its Wegovy pill beat third-quarter sales forecasts, boosting the Danish firm’s bid to win back ground from US rival Eli Lilly.